Screening for Adverse Childhood Experiences

TY - JOUR

T1 - Screening for Adverse Childhood Experiences

AU - Gordon, Jeoffry B.

AU - Nemeroff, Charles B.

AU - Felitti, Vincent

N1 - Funding Information: Funding/Support: Dr Marshall’s contribution to this project was supported in part by the National Institutes of Health/National Cancer Institute (grant T32 CA225617). Dr Korenstein’s contribution to this project was supported in part by a Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center (grant P30 CA008748) from the National Cancer Institute. Funding Information: California Citizens Review Panel on Critical Incidents. Dr Nemeroff reported receiving grants from the National Institutes of Health; consulting for Xhale, Takeda, Taisho Pharmaceutical Inc, Signant Health, Sunovion Pharmaceuticals Inc, Janssen Research & Development LLC, Magstim Inc, Navitor Pharmaceuticals Inc, TC MSO Inc, Intra-Cellular Therapies Inc, EMA Wellness, Gerson Lehrman Group, Acadia Pharmaceuticals, Magnolia CNS, Compass Pathways, Epiodyne, Sophos, and Axioma; being a stockholder in Xhale, Celgene, Seattle Genetics, AbbVie, OPKO Health Inc, Antares, BI Gen Holdings Inc, Corcept Therapeutics Pharmaceuticals Company, TC MSO Inc, Trends in Pharma Development LLC, and EMA Wellness; serving on scientific advisory boards for the American Foundation for Suicide Prevention, the Brain and Behavior Research Foundation, Xhale, Anxiety Disorders Association of America, Skyland Trail, Signant Health, Laureate Institute for Brain Research Inc, and Magnolia CNS; serving on the board of directors of Gratitude America, Anxiety Disorders Association of America, and Xhale Smart Inc; income sources or equity of $10 000 or more from American Psychiatric Publishing, Xhale, Signant Health, CME Outfitters, Intra-Cellular Therapies Inc, Magstim, and EMA Wellness; and holding patents for method and devices for transdermal delivery of lithium, method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay, and Compounds, Compositions, Methods of Synthesis, and Methods of Treatment (CRF receptor binding ligand). Dr Felitti reported being the co–principal investigator of the Adverse Childhood Experiences Study. 1. Campbell TL. Screening for adverse childhood experiences (ACEs) in primary care: a cautionary note. JAMA. 2020;323(23):2379-2380. doi:10.1001/jama. 2020.4365 2. Dubowitz H, Lane WG, Semiatin JN, Magder LS. The SEEK model of pediatric primary care: can child maltreatment be prevented in a low-risk population? Acad Pediatr. 2012;12(4):259-268. doi:10.1016/j.acap.2012.03.005 3. Bethell CD, Davis MB, Gombojav N, Stumbo S, Powers K. Issue Brief: Adverse Childhood Experiences Among US Children. Childhood and Adolescent Health Measurement Initiative; 2017. Accessed August 5, 2020. https://www.cahmi. org/projects/adverse-childhood-experiences-aces/ 4. Kaufman J, Yang B-Z, Douglas-Palumberi H, et al. Social supports and serotonin transporter gene moderate depression in maltreated children. Proc Natl Acad SciUSA. 2004;101(49):17316-17321. doi:10.1073/pnas.0404376101 5. Felitti VJ, Anda RF. The lifelong effects of adverse childhood experiences. In: Chadwick DL, Giardino AP, Alexander R, Thackeray JD, Esernio-Jenssen D, eds. Child Maltreatment, Vol 2: Sexual Abuse and Psychological Maltreatment. 4th ed. STM Learning Inc; 2014:203-216.

PY - 2020/11/3

Y1 - 2020/11/3

UR - http://www.scopus.com/inward/record.url?scp=85095671506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85095671506&partnerID=8YFLogxK

U2 - 10.1001/jama.2020.16449

DO - 10.1001/jama.2020.16449

M3 - Letter

C2 - 33141202

AN - SCOPUS:85095671506

VL - 324

SP - 1788

EP - 1789

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 17

ER -